Medical-device maker Boston Scientific slashed its forecast of full-year 2026 revenue Wednesday, citing softer-than-expected sales in areas like kidney-stone devices and its Watchman heart-rhythm device. Yet the company’s share price surged 8% Wednesday, on pace for its largest percent increase sin